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Background: Percutaneous closure of patent foramen ovale (PFO) became a widely used procedure in patients with suspected paradoxical 
embolism. The aim of our study was to assess the functional effects of closure device on the aortic and tricuspid valve.
Methods: We analized 213 consecutive patients who underwent PFO closure from 2002 until 2008. Clinical and echocardiographic examination 
was performed before and 6 months after the procedure to evaluate heart valve function.
Results: Implantation was successful in all patients, however 3 patients required a second intervention. 1 patient with device embolization and 2 
patients with residual shunt had to undergo a second intervention. Significant residual shunt (> 20 microbubbles) was documented in 10 patients 
(4.7%) at follow-up. Newly developed or worsened aortic vlave regurgitation (AR) was found in 19 patients (8.9%) whereas newly developed or 
worsened tricuspid valve regurgitation (TR) was documented in 52 patients (24.4%).
Conclusions: AR occurred in 8.9% of patients undergoing percutaneous PFO closure whereas 24.4% developed TR. Despite a generally safe 
procedure this potential complication should be considered. Long-term follow-up will be needed to assess hemodynamical and clinical relevance of 
these findings.
